zithromax and Eye-Diseases

We evaluated the clinical features of postoperative anterior blepharitis following cataract surgery and the efficacy of topical azithromycin retrospectively. Thirty eyes of 30 patients with a clinical diagnosis of anterior blepharitis by 6 months postoperatively among those who underwent cataract surgery at our institution between November 2020 and June 2022 were included. The diagnosis of anterior blepharitis and the assessment of objective and subjective findings were based on the American Academy of Ophthalmology Blepharitis Preferred Practice Pattern

Topics: Anti-Bacterial Agents; Azithromycin; Blepharitis; Cataract; Eye Diseases; Foreign Bodies; Humans; Inflammation; Meibomian Gland Dysfunction; Ophthalmic Solutions; Retrospective Studies

We investigated antimicrobial drug resistance in ocular Chlamydia trachomatis 18 months after 4 biannual communitywide distributions of antimicrobial drugs in a region of Ethiopia where ocular strains of C. trachomatis are highly endemic. We found no significant differences in susceptibilities to azithromycin and doxycycline in 6 posttreatment and 4 pretreatment samples.

Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Chlamydia trachomatis; Cycloheximide; Drug Resistance, Microbial; Ethiopia; Eye Diseases; Female; Genetic Predisposition to Disease; Humans; Infant; Male; Pregnancy; Pregnancy Complications, Infectious; Prevalence

Topics: Adenoviridae Infections; Administration, Topical; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Clinical Trials, Phase I as Topic; Conjunctivitis; Corneal Ulcer; Dexamethasone; Diagnostic Techniques, Ophthalmological; Drug Combinations; Drug Delivery Systems; Eye Diseases; Glucocorticoids; Humans; Phenytoin; Sclera; United States; United States Food and Drug Administration

Topics: Administration, Oral; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azithromycin; Cloprostenol; Eye Diseases; Glaucoma, Open-Angle; Humans; Macular Degeneration; Ocular Hypertension; Ranibizumab; Recurrence; Risk Factors; Stroke; Trachoma; Travoprost